XORTX Therapeutics Inc. develops therapies for gout and progressive kidney disease, with programs that include XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections, and XRx-225 for Type 2 diabetic nephropathy. The company also holds the VB4-P5 kidney anti-fibrotic program, a pre-IND asset targeting rare and prevalent forms of kidney disease.
Company announcements cover clinical and preclinical pipeline development, acquired kidney-disease assets, share consolidations, Nasdaq and TSX Venture Exchange listing matters, annual meeting results, board elections, auditor appointments, stock option plan approvals, and other governance actions tied to its public-company status.
XORTX Therapeutics, a late-stage clinical pharmaceutical company focused on treating progressive kidney disease, announces its participation in the BIO International Convention 2024 from June 3-6 at the San Diego Convention Center. CEO Dr. Allen Davidoff will present an overview of the company's progress and future plans on June 4 at 3:30 pm in Theater 1. The event aims to foster outreach to pharmaceutical partners and industry contacts, with over 25 meetings scheduled. One-on-one meetings with Dr. Davidoff can be arranged through the BIO International 2024 meeting platform.
XORTX Therapeutics announced the repricing of warrants issued in October 2021, receiving approval from the TSX Venture Exchange to amend the terms. The repricing affects 101,111 warrants post a 9:1 consolidation, lowering the exercise price from USD $42.93 to USD $5.00. If the company's stock price exceeds USD $6.50 for ten consecutive trading days, warrant holders must exercise their options within 30 days or face expiration.
XORTX Therapeutics Inc. announces the amendment of 1,024,099 outstanding common share purchase warrants by changing the exercise price to USD $5.00 per share. The TSX Venture Exchange approved the amendments related to Private Placements from 2021 to 2022. Additionally, a new Warrant Acceleration Provision was introduced.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.